Objectives To describe muscle-related statin adverse effects in real-world pediatric practice. Study design Using prospectively collected quality improvement data from a pediatric preventive cardiology practice, we compared serum creatine kinase (CK) levels among patients prescribed and not prescribed statins, and pre-/poststatin initiation. Multivariable mixed-effect models were constructed accounting for repeated measures, examining the effect of statins on log-transformed CK (lnCK) levels adjusted for age, sex, weight, season, insurance type, and race/ethnicity.
S
tatins (hydroxy-methylglutaryl-coenzyme A reductase inhibitors) are recommended for children and adolescents with severe lipid disorders that are not sufficiently responsive to lifestyle modification to reduce the risk of future atherosclerotic cardiovascular disease (ASCVD) events. 1 However, the benefits of statins in high-risk youth must be weighed against potential adverse effects, particularly because children who are prescribed these medicines often have a genetic hyperlipidemia, and are likely to take statins for decades. Muscle toxicity, including muscle pain (and rarely rhabdomyolysis), are the most commonly cited adverse effects of statin therapy. 2 Fear of muscle toxicity is a commonly cited reason for delaying or not initiating statin therapy, and minor muscle aches and pains may lead children and adolescents to discontinue statins. It is important to understand the extent of muscle-related adverse effects from statins in youth to avoid inadvertent lost opportunities to reduce future ASCVD.
Muscle-related adverse effects of statins can present as asymptomatic increases in serum creatine kinase (CK), myalgia (muscle complaints without CK elevations), myositis (muscle symptoms accompanied by CK elevations), and rhabdomyolysis (muscle aches or weakness with CK levels >10 times the upper normal limit, and evidence of renal compromise). 3, 4 In clinical trials of adult patients, the incidence of myopathy with minor muscle pain, marked elevations in CK, and rhabdomyolysis are quite rare, occurring at rates of 190, 5, and 1.6 per 100 000 patient years, respectively. 5 Notable rates of myopathy in clinical practice studies in adults vary widely from 0.1% to as high as 33%, possibly because of a higher incidence of comorbidities and less frequent monitoring. [6] [7] [8] In a metaanalysis of randomized controlled trials of statins in children and adolescents with familial hypercholesterolemia, no patients experienced rhabdomyolysis and rates 
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of myopathy were low. 9 Recent trials have confirmed these findings. 10, 11 However, the incidence of statin-associated muscle toxicity in children and adolescents in clinical practice outside of controlled trials is not well described. In this review of data collected for a quality improvement project, we aimed to describe CK levels and muscle-related symptoms in real-world pediatric preventive cardiology practice.
Methods
Patient data were collected from September 2010 to March 2014 in a referral pediatric preventive cardiology clinic at Boston Children's Hospital using the Subspecialty Standardized Clinical Assessment and Management Plan (SCAMP), a quality improvement initiative focusing on pediatric patients with lipid abnormalities. The Subspecialty Lipid SCAMP provides guidance about the evaluation and treatment of children and adolescents with lipid abnormalities, prospectively capturing clinical data and provider decision making to iteratively improve quality of care. 12, 13 This dataset was used to describe clinical characteristics including anthropometrics, family history, medical conditions, and laboratory values. Muscle symptoms were collected, where available, from the SCAMP dataset and from the electronic medical record.
Patients were included in this analysis if they had at least 1 serum CK measurement and were excluded if they had no recorded clinical data or had a condition that could affect CK levels (chronic renal disease, childhood cancer, heart transplant, or inflammatory disease). CK levels were routinely measured as recommended by the SCAMP and based on provider preference in patients prescribed statins or if providers anticipated starting statins at an upcoming visit. Patients were initially categorized into 2 groups: on statins (clinical and laboratory data that occurred in patients who initiated therapy before and during the data capture period) and off statins (clinical and laboratory data that occurred in patients prior to statin therapy or in patients who had CK levels drawn but were never started on statins). Patients started on statins during the observation period, therefore, contribute data to both groups. Patients who started on statins during the observation period were further subdivided into prestatin (data captured before statin therapy was initiated) and poststatin therapy (data captured after statin therapy was initiated) groups. The upper limit of normal (ULN) for CK levels was defined as 175 IU/L for male patients and 150 IU/L for female patients as per Boston Children's Hospital laboratory reference values. Rates of muscleassociated complaints and symptoms were recorded to compare patients on vs off statin therapy. This analysis was approved by the Boston Children's Hospital institutional review board, and individual consent was waived.
The following clinical variables were collected as part of clinical care and recorded in the SCAMP quality improvement dataset: age, sex, race and ethnicity (self-reported at visit checkin), family history of hypercholesterolemia or early ASCVD (defined as fatal or nonfatal ASCVD in a first-degree relative ≤55 years in male subjects or ≤65 years in female subjects 1 ), medical conditions (elevated blood pressure, clinical suspicion of insulin resistance, type I or II diabetes mellitus), height, weight, body mass index (BMI), as well as their associated z scores calculated from the age-sex derived Center for Disease Control database, blood pressure, insurance type (public vs private), and adequate physical activity levels determined by the clinician based on patient/family self-report as approximately ≥5 hours per week. Obesity was defined as BMI ≥95th percentile (<18 years of age) or BMI ≥30 kg/m 2 (≥18 years of age) and overweight was defined as BMI 85th-94th percentile for age and sex (<18 years of age) or between 25 and 29 kg/ m 2 (≥18 years of age). These data were captured on the SCAMP form at the time of the initial visit by the medical provider.
Laboratory values including CK, fasting (≥8 hours) total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels were obtained at baseline and follow-up visits. Patients had blood samples drawn at Boston Children's Hospital or at their local laboratories as convenient for the patient. CK levels ULN ≥3 SDs above the mean were confirmed in the patient's medical record.
Statin-associated myopathy was defined as (1) any descriptions of myopathy recorded by the provider in the SCAMP or (2) CK levels >3× or >10× ULN.
Statistical Analyses
Patient characteristics for all patients were described with means (SD), medians (IQR), and frequencies, as appropriate for distribution. Linear mixed-effects models with restricted maximum likelihood estimation were constructed to test the association of statin therapy with serum CK levels in the overall study sample. Subject identification (ID) was specified as a random effect, an unstructured covariance structure was selected, and 2 successive models were run: (1) adjusted for age and sex, (2) additionally adjusted for season at time of CK measurement, as physical activity might vary based on time of year, weight category (obese, overweight, and normal), insurance type (public or private), and race/ethnicity as fixed effects. To test the association of statin therapy with the odds of developing high CK levels (>ULN vs normal), generalized linear mixedeffect models fit by maximum likelihood (Laplace Approximation), binomial distribution (logit link), with subject ID as a random effect and age and sex as fixed effect were conducted. Regression models failed to converge when the elevated CK group was divided into further subgroups (eg, >3× or >10× ULN) because of low event rates and are, therefore, presented descriptively only.
For patients who initiated statin therapy during the SCAMP data capture, age-and sex-adjusted linear mixed-effect models with subject ID as a random effect were constructed to test the association of statin therapy with serum CK levels among the same set of patients prior to and after initiation of statins. In addition, age-and sex-adjusted linear mixed models for longitudinal data, allowing random intercepts for each patient, were employed to determine the rate of change in CK levels over time after initiating statins. Models allowing both random slopes and intercepts did not improve model fit (as determined by Akaike information criterion when using maximum likelihood estimation), and, therefore, only the more parsi-monious model with random intercepts was run. Analyses used the nlme 14 
Results
Of the 1501 patients included in the database, 474 patients had CK levels and met other criteria for analysis (Figure 1 ; available at www.jpeds.com). Included patients had a mean (SD) age of 14.3 ± 4.0 years; 47% were female, 65% were Caucasian, and 7% were African American (Table) . The analyzed patients had 1450 serum CK laboratory values, an average of 3. 
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Among the 474 included patients, the percent of abnormal CK values did not substantially differ among patients on statins compared with patients not on statin therapy. Among those on statins (n = 188 patients, 768 CK measurements), 20% (153) of values were 1-3 × ULN and 2.2% (17) were >3× ULN. Similarly, among those not on statin therapy (n = 351 patients, 682 CK measurements), 22% (150) and 2.5% (17) were 1-3× ULN and >3× ULN, respectively. Four patients included in the dataset had at least 1 CK value >10× ULN noted during routine monitoring after 6 or more months on statins. All were asymptomatic. The abnormal CK levels were variably addressed by encouraging fluids, limiting physical activity, holding statins, and repeating CK levels based on clinician and patient/family preference; CK levels normalized in all cases without additional intervention. All 4 patients were on statin therapy at the time of the last clinical interaction. The OR for an elevated CK (>ULN) among statin users compared with patients not on statins was not elevated (OR = 0.97 [95% 0.6-1.5]; P = .9), in age-and sex-adjusted mixed-effect model accounting for repeated measures.
Median CK levels for each patient prior to and after initiation of statin therapy are outlined in (Figure 3 ; available at www.jpeds.com). In the adjusted linear mixed-effects model, there was no observed difference between pre-and poststatin CK values for those patients who began statin therapy during the data capture period in age-and sex-adjusted or multivariable-adjusted models (b for statin use on lnCK = .08 [SE .06], P = .2 and b for statin use on lnCK = .08 [SE .07], P = .2, respectively). Among the 86 patients starting statins during the observation period (130 CK measures pre and 292 CK measures post), the OR for elevated CK levels (>ULN compared with normal [ref] ) after initiating statin therapy compared with prior to statin use was not elevated in our study sample; OR = 1.4 ([95% 0.9-2.2]; P = .3) in age-and sexadjusted regression models. There were too few CK levels >3× or >10× ULN to conduct further elevated CK group inference testing. Absolute change in serum CK level from baseline is shown in Figure 4 (available at www.jpeds.com). When CK levels of patients on statins are assessed over time, CK levels increase marginally with statin use by 1.08 (95% CI 1.004, 1.18) IU/L per year (b for time after starting statins on lnCK = .084 [SE .04] increase per year, n = 86, P = .04), an increase without clinical significance.
Myopathies and Symptoms
Rates of associated myopathy including myalgia, myositis, and rhabdomyolysis across all statin users were examined. There were no reported episodes of rhabdomyolysis. Out of all new statin starts and patients already on statins at the time of the SCAMP initiation, only 1 patient reported muscle pain with elevated CK. These symptoms were mild, resolved with the application of heat, and then ceased without any change in the statin dose or type. This single report of mild symptoms was obtained from a total of 3433 patient-months of follow-up on 171 patients treated with statins during the observation period (with over 1 CK measurement or a baseline statin start date), giving an incidence of 0.3 minor events per 100 patientyears of follow-up.
Discussion
In this study, we examined serum CK levels and reported muscle symptoms in children and adolescents treated with statins compared with untreated levels including subset analyses of the same pediatric patients prior to and after statin initiation, and change in CK levels over time on statins. We found no clinically meaningful differences in CK levels off vs on statins, or after statin initiation. CK levels increased very slightly over time on statins (~1 IU/L per year), a clinically insignificant change. A single report of muscle symptoms was noted in a patient with elevated CK and resolved without intervention. Four patients had CK elevation >10× ULN while on statin therapy, without accompanying symptoms; these patients were managed expectantly and at the last clinical encounter remained on statins with normal CK levels.
Understanding of statin-related muscle toxicity in the pediatric patient population comes primarily from randomized controlled trials of statins in children and adolescents with familial hypercholesterolemia. In a meta-analysis of statin trials in children and adolescents treated with statins, muscleassociated symptoms and elevated serum CK levels were reported at very low prevalence. 9 Of the 21 included studies, 5 reported CK levels; there was no increased risk for CK levels >10× ULN. There were no cases of rhabdomyolysis. There are limited data representing clinical practice outside of the clinical trial setting. One survey of young adults taking statins over 10 years reported muscle symptoms in 9.3% (19/205 patients); no CK levels were collected in this report. 16 Early data from a United Kingdom pediatric familial hypercholesterolemia registry reported no significant CK elevations in 111 children on statins. 17 Neither study reported episodes of rhabdomyolysis. The National Heart Blood and Lung Institute Expert Panel in 2011 recommends a baseline CK measurement prior to statin initiation and regular monitoring of myopathy-associated symptoms by patients and parents.
1 CK levels are recommended when patients experience symptoms. However, some practices regularly measure CK levels in asymptomatic patients as part of ongoing clinical monitoring. Increased physical activity levels are recommended to reduce cardiovascular risk but complicate the interpretation of CK levels and muscle symptoms in children on statins. Concerns have been raised about adverse effects of statins in children, particularly in light of the growing evidence of the early origins of ASCVD. 18 Our study provides greater understanding of the prevalence of statin-associated adverse effects and their relation to serum CK levels in clinical practice, outside the confines of clinical trials this understudied group. The findings support recommendations for the judicious use of CK levels, given that our clinical experience in monitoring of CK levels in asymptomatic pediatric patients on statin therapy did not provide any useful additional information.
This analysis has several limitations. Although our cohort was relatively large for pediatric patients on statins, it was not large enough to reliably detect rare events (eg, rhabdomyolysis). This analysis was a review of clinical experience collected as part of a quality improvement effort, not a clinical trial, so our comparison group was not randomly ascertained. Similarly, symptoms were not systematically collected in patients not prescribed statins. During this time, physical activity was not systematically collected as part of the quality improvement dataset, and, therefore, we were not able to adjust for activity level among our patients, who were receiving advice to participate in regular moderate to vigorous physical activity. In addition, serum CK levels were more likely to be drawn in patients with symptoms on statins, skewing the number of values toward those on statin therapy. We were not able to examine dose or statin type because most patients were on 1 of 2 low dose statins (simvastatin or atorvastatin), limiting the variability in statin type and dose. The design of the quality improvement dataset did not capture medication or dose changes during follow-up. Frequency of follow-up differed among patients on vs not on statin therapy. Furthermore, the patients included in this study were referred to and cared for in a pediatric subspecialty lipid clinic and do not reflect a primary care practice; most children on statins are cared for by subspecialists. The majority of patients were Caucasian, and our results may not be generalizable to other ethnicities.
Our findings suggest limited utility to monitoring CK levels in asymptomatic pediatric patients on statins, supporting the recommendations of the National Heart Blood and Lung Institute Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. 
